Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy
Cristina Ferreras, B. Pascual-Miguel, Carmen Mestre-Durán, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses
Agnes Bonifacius, Sabine Tischer‐Zimmermann, Anna Christina Dragon, et al.
Immunity (2021) Vol. 54, Iss. 2, pp. 340-354.e6
Open Access | Times Cited: 206
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
Αναστασία Παπαδοπούλου, George Karavalakis, Efthymia Papadopoulou, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2019-2029
Closed Access | Times Cited: 23
Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19
Mihaela Chivu‐Economescu, Coralia Bleoţu, Camelia Grancea, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 4, pp. 1293-1305
Open Access | Times Cited: 36
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly
Blood (2022) Vol. 140, Iss. 7, pp. 673-684
Open Access | Times Cited: 28
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
Antonio Pérez‐Martínez, Marta Mora-Rillo, Cristina Ferreras, et al.
EClinicalMedicine (2021) Vol. 39, pp. 101086-101086
Open Access | Times Cited: 32
Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
Lara Herrera, Myriam Martin‐Inaraja, Silvia J. Santos, et al.
Immunology (2021) Vol. 165, Iss. 2, pp. 234-249
Open Access | Times Cited: 29
HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses
Pavlo A. Nesterenko, Jami McLaughlin, Brandon L. Tsai, et al.
Cell Reports (2021) Vol. 37, Iss. 13, pp. 110167-110167
Open Access | Times Cited: 28
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Keywan Mortezaee, Jamal Majidpoor
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
Archana Panikkar, Katie E. Lineburg, Jyothy Raju, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 2, pp. e1010339-e1010339
Open Access | Times Cited: 19
SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response
Chanchan Xiao, Lipeng Mao, Zhigang Wang, et al.
iScience (2022) Vol. 25, Iss. 3, pp. 103934-103934
Open Access | Times Cited: 19
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)
Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín‐Quirós, et al.
Cytotherapy (2023) Vol. 26, Iss. 1, pp. 25-35
Closed Access | Times Cited: 11
Familial CD45RA– T cells to treat severe refractory infections in immunocompromised patients
Karima Al‐Akioui‐Sanz, Carlos Echecopar, Cristina Ferreras, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Organoid modeling of lung-resident immune responses to SARS-CoV-2 infection
Calvin J. Kuo, S. S. Choi, Vincent van Unen, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 7
Central and effector memory T cells in peripheral blood of patients with interstitial pneumonia: preliminary clues from a COVID-19 study
Makhabbat Bekbossynova, Lyudmila Akhmaltdinova, Kuanysh Dossybayeva, et al.
Respiratory Research (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Immune cell landscape in symptomatic and asymptomatic SARS-CoV-2 infected adults and children in urban Dhaka, Bangladesh
Evana Akhtar, Akhirunnesa Mily, Protim Sarker, et al.
Immunobiology (2023) Vol. 228, Iss. 2, pp. 152350-152350
Open Access | Times Cited: 5
Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment
Nayoun Kim, Jong Min Lee, Eun‐Jee Oh, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 12
Alterations of Urinary Microbial Metabolites and Immune Indexes Linked With COVID-19 Infection and Prognosis
Yixian Jing, Jing Wang, Haiyan Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Immunologic mediators profile in COVID-19 convalescence
Alexander Leonardo Silva-Junior, Lucas Silva de Oliveira, Stephanny Dias, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients
Alexander Leonardo Silva-Junior, Lucas da Silva Oliveira, Nara Caroline Toledo Belezia, et al.
Immuno (2023) Vol. 3, Iss. 1, pp. 86-111
Open Access | Times Cited: 4
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
László Gopcsa, Marienn Réti, Hajnalka Andrikovics, et al.
GeroScience (2023) Vol. 46, Iss. 1, pp. 1083-1106
Open Access | Times Cited: 4
A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
Irene García-García, Pilar Guerra‐García, Cristina Ferreras, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Rifampicin for COVID-19
George Panayiotakopoulos, Dimitrios T. Papadimitriou
World Journal of Virology (2022) Vol. 11, Iss. 2, pp. 90-97
Open Access | Times Cited: 6
Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects
Rubén Gil-Bescós, Ainhoa Ostiz, Saioa Zalba, et al.
Life Science Alliance (2023) Vol. 6, Iss. 6, pp. e202201759-e202201759
Open Access | Times Cited: 3
SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
José Luís Piñana, Manuel Guerreiro, Carlos Solano
Hemato (2023) Vol. 4, Iss. 2, pp. 170-183
Open Access | Times Cited: 3
COVID-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions
Babak Arjmand, Sepideh Alavi-Moghadam, Peyvand Parhizkar Roudsari, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top